Trial Profile

An Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 21 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pozelimab (Primary) ; Pozelimab (Primary)
Indications Protein-losing enteropathy
Focus First in man; Registrational; Therapeutic Use
Sponsors Regeneron Pharmaceuticals

Most Recent Events

08 May 2024 Status changed from active, no longer recruiting to completed.
05 Feb 2024 Results of Evaluating the efficacy and safety of pozelimab published in the Lancet
18 Aug 2023 "According to Regeneron media release, Michael Lenardo is an investigator of the trial."

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com